Table 2.
Neuraminidase inhibition assay comparison using antigens with native viral HA versus HA novel to host
| Human volunteer | NI titers to N1NewCal/99 | NI titers to N2Wis/05 | ||
|---|---|---|---|---|
| H1N1* | H6N1** | H3N2*** | H6N2† | |
| #3 | 160 | 80 | 40 | 20 |
| #4 | 20 | 10 | 20 | 20 |
| #5 | 5 | <5 | 40 | 20 |
| #6 | 40 | 20 | 10 | 10 |
| #7 | 20 | 10 | 20 | 20 |
| #13 | 160 | 40 | 80 | 40 |
| #18 | 80 | 80 | 20 | 20 |
| #25 | ≥320 | 160 | 20 | 20 |
| #26 | 40 | 5 | 80 | 80 |
NI, neuraminidase inhibition; HA, hemagglutinin.
*Tested against wild‐type A/New Caledonia/20/1999.
**Tested against reverse genetics‐derived virus with H6 HA and N1NewCal/99 genes.
***Tested against A/Wisconsin/67/2005 × 161B.
†Tested against reverse genetics‐derived virus with H6 HA and N2Wis/05 genes.